Abel Jasovich

773 total citations
22 papers, 439 citations indexed

About

Abel Jasovich is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, Abel Jasovich has authored 22 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 13 papers in Epidemiology and 8 papers in Molecular Medicine. Recurrent topics in Abel Jasovich's work include Antibiotics Pharmacokinetics and Efficacy (13 papers), Pneumonia and Respiratory Infections (10 papers) and Antibiotic Resistance in Bacteria (8 papers). Abel Jasovich is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (13 papers), Pneumonia and Respiratory Infections (10 papers) and Antibiotic Resistance in Bacteria (8 papers). Abel Jasovich collaborates with scholars based in Argentina, United States and Colombia. Abel Jasovich's co-authors include Rajiv Mallick, María Eugenia Oliva, Gary Dukart, Carlos Bergallo, Koné Kaniga, Christopher Lucasti, Obiamiwe Umeh, Ian R. Friedland, Joel Jiang and Walter Krause Neto and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Transplantation.

In The Last Decade

Abel Jasovich

22 papers receiving 405 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abel Jasovich Argentina 10 226 211 202 89 76 22 439
Jerome J. Schentag United States 10 336 1.5× 221 1.0× 197 1.0× 84 0.9× 82 1.1× 14 576
Patrick McLeroth United States 8 239 1.1× 195 0.9× 331 1.6× 150 1.7× 93 1.2× 12 554
C. Angel Cooper United States 7 299 1.3× 238 1.1× 370 1.8× 124 1.4× 133 1.8× 8 611
Matthew F. Wack United States 10 204 0.9× 197 0.9× 78 0.4× 82 0.9× 72 0.9× 15 443
Pornpan Koomanachai Thailand 11 272 1.2× 165 0.8× 285 1.4× 93 1.0× 111 1.5× 29 473
D. Hoban Canada 11 114 0.5× 180 0.9× 161 0.8× 41 0.5× 109 1.4× 12 400
Jean Li Yan United States 13 238 1.1× 226 1.1× 234 1.2× 74 0.8× 198 2.6× 28 546
Csaba Fehér Spain 14 157 0.7× 190 0.9× 180 0.9× 104 1.2× 119 1.6× 23 482
Carolina Saffioti Italy 8 155 0.7× 176 0.8× 269 1.3× 140 1.6× 89 1.2× 30 466
Sean Nguyen United States 14 124 0.5× 176 0.8× 105 0.5× 90 1.0× 139 1.8× 32 481

Countries citing papers authored by Abel Jasovich

Since Specialization
Citations

This map shows the geographic impact of Abel Jasovich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abel Jasovich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abel Jasovich more than expected).

Fields of papers citing papers by Abel Jasovich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abel Jasovich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abel Jasovich. The network helps show where Abel Jasovich may publish in the future.

Co-authorship network of co-authors of Abel Jasovich

This figure shows the co-authorship network connecting the top 25 collaborators of Abel Jasovich. A scholar is included among the top collaborators of Abel Jasovich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abel Jasovich. Abel Jasovich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bantar, Carlos, Daniel Curcio, Abel Jasovich, et al.. (2010). Updated Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from the South American Working Group (Consensur II). Current Respiratory Medicine Reviews. 6(2). 102–123. 3 indexed citations
2.
3.
Jasovich, Abel, et al.. (2009). Tigeciclina versus vancomycin más aztreonam en el tratamiento de infecciones complicadas de piel y tejidos blandos: Experiencia en Latinoamérica. Revista chilena de infectología. 26. 23–31. 1 indexed citations
4.
Jasovich, Abel, et al.. (2009). Endocarditis due to vancomycin-resistant Enterococcus raffinosus successfully treated with linezolid: case report and review of literature.. PubMed. 40(4). 204–7. 9 indexed citations
5.
Lucasti, Christopher, Abel Jasovich, Obiamiwe Umeh, et al.. (2008). Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clinical Therapeutics. 30(5). 868–883. 79 indexed citations
6.
Bergallo, Carlos, Abel Jasovich, María Eugenia Oliva, et al.. (2008). Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagnostic Microbiology and Infectious Disease. 63(1). 52–61. 73 indexed citations
7.
Tănăseanu, Cristina, Carlos Bergallo, Abel Jasovich, et al.. (2008). Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease. 61(3). 329–338. 93 indexed citations
8.
Lucasti, Christopher, Abel Jasovich, Obiamiwe Umeh, Junguang Jiang, & Koné Kaniga. (2007). P834 Treatment of complicated intra-abdominal infections: doripenem versus meropenem. International Journal of Antimicrobial Agents. 29. S212–S212. 7 indexed citations
9.
Bantar, Carlos, et al.. (2006). Review of Pharmacokinetic, Pharmacodynamic and Clinical Studies with a Modern Combination of Amoxicillin/Sulbactam. Chemotherapy. 52(4). 200–204. 6 indexed citations
10.
Jasovich, Abel. (2003). El control de los antibióticos: ¿hasta donde duela?. Revista chilena de infectología. 20. 4 indexed citations
11.
Curcio, Daniel, Homero Bagnulo, Luis Bavestrello, et al.. (2002). Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from a South American Working Group (ConsenSur). Journal of Chemotherapy. 14(sup4). 1–24. 9 indexed citations
12.
13.
14.
Bantar, Carlos, Federico Nicola, Liliana Fernández Canigia, et al.. (2001). Rationale for Treating Community-Acquired Lower Respiratory Tract Infections with Amoxicillin/Sulbactam Combination Through Pharmacodynamic Analysis in the Setting of Aminopenicillin-Resistant Organisms. Journal of Chemotherapy. 13(4). 402–406. 5 indexed citations
15.
Jasovich, Abel. (2001). Amoxicillin-sulbactam: A combination with a soundpharmacokinetic-pharmacodynamic basis. Drugs of today. 37(3). 187–187. 1 indexed citations
16.
Bantar, Carlos, Federico Nicola, Liliana Fernández Canigia, et al.. (2000). A Pharmacodynamic Model to Support a 12-Hour Dosing Interval for Amoxicillin/Sulbactam, a Novel Oral Combination, in the Treatment of Community-Acquired Lower Respiratory Tract Infections. Journal of Chemotherapy. 12(3). 223–227. 8 indexed citations
17.
Altclas, Javier, et al.. (1992). [Microbiology and conservative surgery of serious infections of the diabetic foot].. PubMed. 10(8). 451–5. 4 indexed citations
18.
Jasovich, Abel, et al.. (1992). Chagas' disease and kidney transplantation--follow-up of nine patients for 11 years.. PubMed. 24(6). 3089–90. 15 indexed citations
19.
Stamboulián, Daniel, et al.. (1985). Comparative Clinical Evaluation of Imipenem/Cilastatin vs. Cefotaxime in Treatment of Severe Bacterial Infections. Clinical Infectious Diseases. 7(Supplement_3). S458–S462. 9 indexed citations
20.
Jasovich, Abel, et al.. (1983). KIDNEY TRANSPLANTATION AND CHAGASʼ DISEASE. Transplantation. 36(2). 211–212. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jerome J. Schentag Breakdown of academic impact, for papers by Patrick McLeroth Breakdown of academic impact, for papers by C. Angel Cooper Breakdown of academic impact, for papers by Matthew F. Wack Breakdown of academic impact, for papers by Pornpan Koomanachai Breakdown of academic impact, for papers by D. Hoban Breakdown of academic impact, for papers by Jean Li Yan Breakdown of academic impact, for papers by Csaba Fehér Breakdown of academic impact, for papers by Carolina Saffioti Breakdown of academic impact, for papers by Sean Nguyen
Rankless by CCL
2026